Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 10/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29582422 | 1.00 | MAOB (0.46) | MAOBMAOAPRKCIMIFCYP26A1 | |
| SCHEMBL15173274 | 0.81 | SRD5A1 (0.45) | CYP19A1 | |
| SCHEMBL453375 | 0.81 | MIF (0.47) | MAOBMAOAPRKCIMIFCYP26A1 | |
| SCHEMBL448275 | 0.78 | MIF (0.47) | MIFCYP26A1CYP19A1 | |
| SCHEMBL31122387 | 0.78 | CYP26A1 (0.41) | MAOBMAOAMIFCYP26A1 | |
| SCHEMBL29582798 | 0.78 | MIF (0.47) | MIFCYP26A1CYP19A1 | |
| SCHEMBL29952458 | 0.77 | ESR1 (0.54) | MAOBMAOACYP19A1 | |
| SCHEMBL2063760 | 0.77 | ESR1 (0.54) | MAOBMAOACYP19A1 | |
| SCHEMBL10088633 | 0.76 | MAOB (0.56) | MAOBMAOAPRKCIMIFCYP19A1 | |
| SCHEMBL25314366 | 0.76 | MAPT (0.41) | MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522554-B2 | Method for preparing intermediate for synthesis of sphingosine-1-phosphate receptor agonist | LG CHEM, LTD. (KR) | 2026-01-13 | — | — | US | disclosed |
| US-20240228461-A1 | NOVEL METHOD FOR PREPARING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | LG CHEM, LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| US-20240228441-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | LG CHEM, LTD. (KR) | 2024-07-11 | — | — | US | disclosed |
| US-20240217935-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | LG CHEM, LTD. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-20240217935-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | LG CHEM, LTD. (KR) | 2024-07-04 | — | — | US | disclosed |
| EP-4306514-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | Lg Chem, Ltd. (KR) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306516-A1 | NOVEL METHOD FOR PREPARING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | Lg Chem, Ltd. (KR) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306513-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | Lg Chem, Ltd. (KR) | 2024-01-17 | — | — | EP | disclosed |
| US-20240002322-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | LG CHEM, LTD. (KR) | 2024-01-04 | — | — | US | disclosed |
| CN-117242057-A | Process for preparing intermediates useful in the synthesis of sphingosine-1-phosphate receptor agonists | 株式会社LG化学 | 2023-12-15 | — | — | CN | disclosed |
| US-9540362-B2 | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent | LG LIFE SCIENCES LTD. (KR) | 2017-01-10 | — | — | US | disclosed |
| US-20150376173-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2015-12-31 | — | — | US | disclosed |
| EP-2958913-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG Life Sciences Ltd. (KR) | 2015-12-30 | — | — | EP | disclosed |
| CN-105051037-A | Sphingosine-1-phosphate receptor agonists, method for the preparation thereof and pharmaceutical compositions comprising the same as active agent | LG LIFE SCIENCES LTD | 2015-11-11 | — | — | CN | disclosed |
| WO-2014129796-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2014-08-28 | — | — | WO | disclosed |
| US-8653305-B2 | Compound having S1P receptor binding potency and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-8039674-B2 | Amino-substituted cyclic compound for EDG-1(endothelial differentiation gene) and/or EDG-6-mediated diseases; transplant rejection, autoimmune diseases, allergies, asthma, multiple organ failure, ischemia, reperfusion injury, lung or liver fibrosis; antitumor agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1760071-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376173-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | S1PR1, S1PR2, S1PR5 | MAOB 2718/4885MAOA 2406/4885PRKCI 3034/4885 |
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | S1PR1, S1PR3, EDNRA | MAOB 2098/4885MAOA 2130/4885PRKCI 3388/4885 |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | S1PR1, EDNRA, S1PR3 | MAOB 2137/4885MAOA 2174/4885PRKCI 3315/4885 |
| US-20240002322-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | S1PR5, S1PR1, S1PR3 | MAOB 1983/4885MAOA 2357/4885PRKCI 2452/4885 |
| US-20240228461-A1 | NOVEL METHOD FOR PREPARING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | S1PR1, S1PR2, S1PR5 | MAOB 2712/4885MAOA 3199/4885PRKCI 2136/4885 |
| US-20240217935-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | S1PR4, S1PR1, S1PR3 | MAOB 1796/4885MAOA 1887/4885PRKCI 3464/4885 |
| US-20240228441-A1 | METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | S1PR4, S1PR1, S1PR2 | MAOB 1698/4885MAOA 1834/4885PRKCI 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.